REGULATORY

Govt Giving Advice to Fujifilm after Shelving Decision on Avigan

February 1, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese government is giving Fujifilm Toyama Chemical a full explanation on the rationale of its decision to withhold approval for its antiviral Avigan (favipiravir) for the treatment of COVID-19 and offering related advice. The government revealed this in a…

To read the full story

Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…